Karachun Rita A
SEC CIK 1601572 · EDGAR
BoughtSold
Most active insiders at CHRS, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Ryan Michael Lee | Dir | — | — |
| 2 | McMichael Bryan J | CFO | — | — |
| 3 | O'Donnell-Tormey Jill | Dir | — | — |
| 4 | Newton Charles W. | Dir | — | — |
| 5 | Newcomer Lee Nisley | Dir | — | — |
| 6 | Satvat Ali J. | Dir | — | — |
| 7 | Karachun Rita A | Dir | — | — |
| 8 | Wahlstrom Mats | Dir | — | — |
| 9 | Lanfear Dennis M | Pres, CEO, Dir | — | — |
Transactions 18
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-06-09 18:43 | 2026-06-05 | CHRS | Coherus Oncology, Inc. | Karachun Rita A | Dir | A - Grant | $0.00 | +30.0K | 30.0K | New | $0 |
| DM | 2023-05-05 | 2023-05-03+ | MRK | Merck & Co. | Karachun Rita A | SVP Fince-Gbl Ctrl | M - OptEx | $67.64 | +17.6K | 61.6K | +40% | +$1.19M |
| DM | 2023-05-05 | 2023-05-03+ | MRK | Merck & Co. | Karachun Rita A | SVP Fince-Gbl Ctrl | F - Tax | $118.07 | -602 | 45.7K | -1% | -$71.1K |
| D | 2023-05-05 | 2023-05-04 | MRK | Merck & Co. | Karachun Rita A | SVP Fince-Gbl Ctrl | S - Sale+OE | $117.53 | -15.9K | 45.7K | -26% | -$1.87M |
| D | 2023-05-03 | 2023-05-01 | MRK | Merck & Co. | Karachun Rita A | SVP Fince-Gbl Ctrl | M - OptEx | $115.47 | +930 | 44.9K | +2% | +$107.4K |
| D | 2023-05-03 | 2023-05-01 | MRK | Merck & Co. | Karachun Rita A | SVP Fince-Gbl Ctrl | F - Tax | $115.47 | -319 | 44.6K | -0.7% | -$36.8K |
| 2023-01-25 | 2023-01-23 | MRK | Merck & Co. | Karachun Rita A | SVP Fince-Gbl Ctrl | A - Grant | $109.88 | +2,846 | 43.9K | +7% | +$312.7K | |
| D | 2022-11-01 | 2022-10-28 | MRK | Merck & Co. | Karachun Rita A | SVP Fince-Gbl Ctrl | S - Sale+OE | $100.34 | -32.0K | 41.1K | -44% | -$3.21M |
| DM | 2022-11-01 | 2022-10-28 | MRK | Merck & Co. | Karachun Rita A | SVP Fince-Gbl Ctrl | M - OptEx | $0.00 | +32.0K | 58.1K | +123% | $0 |
| D | 2022-05-05 | 2022-05-04 | MRK | Merck & Co. | Karachun Rita A | SVP Fince-Gbl Ctrl | F - Tax | $87.10 | -326 | 41.1K | -0.8% | -$28.4K |
| D | 2022-05-05 | 2022-05-04 | MRK | Merck & Co. | Karachun Rita A | SVP Fince-Gbl Ctrl | M - OptEx | $87.10 | +949 | 41.4K | +2% | +$82.7K |
| D | 2022-05-04 | 2022-05-03 | MRK | Merck & Co. | Karachun Rita A | SVP Fince-Gbl Ctrl | M - OptEx | $87.65 | +902 | 40.8K | +2% | +$79.1K |
| D | 2022-05-04 | 2022-05-03 | MRK | Merck & Co. | Karachun Rita A | SVP Fince-Gbl Ctrl | F - Tax | $87.65 | -309 | 40.5K | -0.8% | -$27.1K |
| D | 2022-05-03 | 2022-05-01 | MRK | Merck & Co. | Karachun Rita A | SVP Fince-Gbl Ctrl | F - Tax | $88.69 | -318 | 39.9K | -0.8% | -$28.2K |
| D | 2022-05-03 | 2022-05-01 | MRK | Merck & Co. | Karachun Rita A | SVP Fince-Gbl Ctrl | M - OptEx | $88.69 | +928 | 40.2K | +2% | +$82.3K |
| 2022-02-28 | 2022-02-24 | MRK | Merck & Co. | Karachun Rita A | SVP Fince-Gbl Ctrl | A - Grant | $73.51 | +3,478 | 39.3K | +10% | +$255.7K | |
| D | 2021-11-04 | 2021-11-03 | MRK | Merck & Co. | Karachun Rita A | SVP Fince-Gbl Ctrl | S - Sale+OE | $88.45 | -25.0K | 35.8K | -41% | -$2.21M |
| D | 2021-11-04 | 2021-11-03 | MRK | Merck & Co. | Karachun Rita A | SVP Fince-Gbl Ctrl | M - OptEx | $0.00 | +25.0K | 60.8K | +70% | $0 |
Purchase Sale Sale after option exercise All abbreviations